Mankind Pharma acquires Rivotril brand for India, reinforcing focus on chronic CNS therapies

Mankind Pharma Limited has announced its acquisition of the Rivotril brand from Roche for the Indian market. This acquisition grants Mankind Pharma exclusive rights to manufacture, market, and distribute Rivotril across India. Rivotril, known as the innovator brand of clonazepam, is widely prescribed for managing neurological and psychiatric conditions, and is recognised for its strong clinical legacy.

The acquisition aligns with Mankind Pharma’s strategic focus on expanding its presence in the chronic therapies segment, particularly in the central nervous system (CNS) therapy area. The company has been steadily increasing its footprint in chronic therapies through new product launches, in-licensing partnerships, and portfolio expansions across key therapeutic areas. Chronic therapies are becoming a significant part of Mankind Pharma’s overall business as it continues to engage with specialists and key opinion leaders.

Atish Majumdar, Senior President of Sales & Marketing at Mankind Pharma Specialty Business, stated that the acquisition is in line with the company’s strategic focus on chronic and specialty therapies. He highlighted the potential for future expansion through line extensions, addressing the evolving needs of patients and physicians in the CNS therapy area. Mankind Pharma plans to leverage its large field force and nationwide distribution network to enhance the brand’s presence and support healthcare providers in delivering better patient outcomes across India.

Mankind Pharma currently engages with over 500,000 doctors and has established a strong prescription share in the Indian pharmaceutical market. The company’s distribution network enables deep penetration across urban and semi-urban markets, supporting wider access to Rivotril among healthcare institutions and prescribers in India.

About Mankind Pharma

Mankind Pharma is one of India’s largest pharmaceutical companies, focusing on the domestic market with a pan-India presence. The company operates at the intersection of pharmaceutical formulations and consumer healthcare, aiming to provide quality products at affordable prices. Mankind Pharma is a leading player in both acute and chronic therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, and more. The company also has a strong presence in the consumer healthcare sector with category-leading brands. Mankind Pharma’s distribution network includes over 17,700 professionals and a reach extending to over 500,000 doctors across urban and rural markets.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).